Abstract: Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Abstract: An equine gastric health formulation that is operable to heal gastrointestinal disorders such as but not limited to ulcers, wherein the present invention further improves liver function and detoxification of the horse. The formulation of the present invention in a preferred embodiment is water based wherein fifty percent of the formulation is distilled water which is approximately five hundred milliliters. A concentration of one percent of the total solution is formed by origanum vulgare. Another two percent of the formula being represented equally is silybum marianum and taraxacum. Three drops of mentha piperita are also dispensed into the formulation of the present invention. Wherein the formulation includes ten percent of chlorophyllin and thirty seven percent is camelina oil. Additionally, four tablespoons of acacia gum powder are mixed into the formulation.

Abstract: There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

Abstract: Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Abstract: There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Abstract: There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

Abstract: There is provided an improved extraction process for obtaining integral & active thylakoid membranes that have longer shelf-life at room temperature. Particularly, the extract is lyophilized in a solution of PVP and remains stable with at least 80% of its original activity for at least 7 days at room temperature, respectively.

Abstract: There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Abstract: A method of detecting the presence of bioactive molecules in a fluid sample, comprising contacting a solution of a microorganism selected from the group consisting of a monocellular algae and a cyanobacteria with the fluid sample so as to obtain a formulation having a microorganism concentration of 200 000-1×107 cells/mL of fluid sample; incubating the formulation for 10 to 120 minutes at a pH of 7 to 12 and a temperature between 18 and 35° C.; and measuring the fluorescence emitted by the formulation, whereby a fluorescence emitted in the sample that is lower than that in a control sample is an indication that the sample contains a bioactive molecule.

Abstract: A stabilized thylakoid membrane formulation comprising thylakoid membranes in a buffered solution and liposomes, wherein the formulation has a ratio of chlorophyll/liposomes of at least about 10:1. The invention further comprises a method for detecting or quantifying the presence of toxic molecules in a fluid sample, comprising obtaining a stabilized thylakoids membranes formulation; and assessing the photosynthetic efficiency of the thylakoid membranes formulation in the presence of said sample, whereby the molecules are detected when the photosynthetic efficiency is measurably different in the presence versus in the absence of the sample. The present invention also comprises kits using the stabilized thylakoid membranes formulation for detecting and/or quantifying the toxic molecule in a fluid sample.

Abstract: A method of detecting the presence of bioactive molecules in a fluid sample, comprising contacting a solution of a microorganism selected from the group consisting of a monocellular algae and a cyanobacteria with the fluid sample so as to obtain a formulation having a microorganism concentration of 200 000-1×107 cells/mL of fluid sample; incubating the formulation for 10 to 120 minutes at a pH of 7 to 12 and a temperature between 18 and 35° C.; and measuring the fluorescence emitted by the formulation, whereby a fluorescence emitted in the sample that is lower than that in a control sample is an indication that the sample contains a bioactive molecule.

Abstract: A stabilised thylakoid membrane formulation comprising thylakoid membranes in a buffered solution and liposomes, wherein the formulation has a ratio of chlorophyll/liposomes of at least about 10:1. The invention further comprises a method for detecting or quantifying the presence of toxic molecules in a fluid sample, comprising obtaining a stabilised thylakoids membranes formulation; and assessing the photosynthetic efficiency of the thylakoid membranes formulation in the presence of said sample, whereby the molecules are detected when the photosynthetic efficiency is measurably different in the presence versus in the absence of the sample. The present invention also comprises kits using the stabilised thylakoid membranes formulation for detecting and/or quantifying the toxic molecule in a fluid sample.

Abstract: A stabilised thylakoid membrane formulation comprising thylakoid membranes in a buffered solution and liposomes, wherein the formulation has a ratio of chlorophyll/liposomes of at least about 10:1. The invention further comprises a method for detecting or quantifying the presence of toxic molecules in a fluid sample, comprising obtaining a stabilised thylakoids membranes formulation; and assessing the photosynthetic efficiency of the thylakoid membranes formulation in the presence of said sample, whereby the molecules are detected when the photosynthetic efficiency is measurably different in the presence versus in the absence of the sample. The present invention also comprises kits using the stabilised thylakoid membranes formulation for detecting and/or quantifying the toxic molecule in a fluid sample.